drugset / Trial / NCT06016972

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

NCT06016972

Phase 2 Completed 63 enrolled Qlaris Bio, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.

Timeline

Start
2024-03-05
Primary completion
2024-08-20
Completion
2024-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject QLS-111 Unknown 0.015 % Other
Subject QLS-111 Unknown 0.03 % Other
Subject QLS-111 Unknown 0.075 % Other